38584983|t|A Review on Neuroinflammatory Pathway Mediating Through Ang-II/AT1 Receptors and a Novel Approach for the Treatment of Cerebral Ischemia in Combination with ARB's and Ceftriaxone.
38584983|a|Background: Ischemic stroke is one of the prevalent neurodegenerative disorders; it is generally characterized by sudden abruption of blood flow due to thromboembolism and vascular abnormalities, eventually impairing the supply of oxygen and nutrients to the brain for its metabolic needs. Oxygen-glucose deprived conditions provoke the release of excessive glutamate, which causes excitotoxicity. Summary: Recent studies suggest that circulatory angiotensin-II (Ang-II) has an imperative role in initiating detrimental events through binding central angiotensin 1 (AT1) receptors. Insufficient energy metabolites and essential ions often lead to oxidative stress during ischemic reperfusion, which leads to the release of proinflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and cytokines like interleukin-18 (IL-18) and interleukin- 1beta (IL-1beta). The transmembrane glutamate transporters, excitatory amino acid transporter-2 (EAAT-2), which express in astroglial cells, have a crucial role in the clearance of glutamate from its releasing site and convert glutamate into glutamine in normal circumstances of brain physiology. Key Message: During cerebral ischemia, an impairment or dysfunction of EAAT-2 attributes the risk of delayed neuronal cell death. Earlier studies evidencing that angiotensin receptor blockers (ARB) attenuate neuroinflammation by inhibiting the Ang-II/AT1 receptor-mediated inflammatory pathway and that ceftriaxone ameliorates the excitotoxicity-induced neuronal deterioration by enhancing the transcription and expression of EAAT-2 via the nuclear transcriptional factor kappa-B (NF-kB) signaling pathway. The present review will briefly discuss the mechanisms involved in Ang-II/AT1-mediated neuroinflammation, ceftriaxone-induced EAAT-2 expression, and the repurposing hypothesis of the novel combination of ARBs and ceftriaxone for the treatment of cerebral ischemia.
38584983	12	29	Neuroinflammatory	Disease	MESH:D000090862
38584983	56	62	Ang-II	Gene	183
38584983	119	136	Cerebral Ischemia	Disease	MESH:D002545
38584983	167	178	Ceftriaxone	Chemical	MESH:D002443
38584983	192	207	Ischemic stroke	Disease	MESH:D002544
38584983	232	259	neurodegenerative disorders	Disease	MESH:D019636
38584983	332	347	thromboembolism	Disease	MESH:D013923
38584983	352	374	vascular abnormalities	Disease	MESH:D014652
38584983	411	417	oxygen	Chemical	MESH:D010100
38584983	470	476	Oxygen	Chemical	MESH:D010100
38584983	477	484	glucose	Chemical	MESH:D005947
38584983	538	547	glutamate	Chemical	MESH:D018698
38584983	562	576	excitotoxicity	Disease	
38584983	627	641	angiotensin-II	Gene	183
38584983	643	649	Ang-II	Gene	183
38584983	851	859	ischemic	Disease	MESH:D002545
38584983	937	950	interleukin-6	Gene	3569
38584983	952	956	IL-6	Gene	3569
38584983	959	986	tumor necrosis factor-alpha	Gene	7124
38584983	988	997	TNF-alpha	Gene	7124
38584983	1019	1033	interleukin-18	Gene	3606
38584983	1035	1040	IL-18	Gene	3606
38584983	1046	1064	interleukin- 1beta	Gene	3553
38584983	1066	1074	IL-1beta	Gene	3553
38584983	1119	1154	excitatory amino acid transporter-2	Gene	6506
38584983	1156	1162	EAAT-2	Gene	6506
38584983	1240	1249	glutamate	Chemical	MESH:D018698
38584983	1286	1310	glutamate into glutamine	ProteinMutation	tmVar:p|SUB|E||Q;VariantGroup:0;CorrespondingGene:6506;CorrespondingSpecies:9606
38584983	1376	1393	cerebral ischemia	Disease	MESH:D002545
38584983	1427	1433	EAAT-2	Gene	6506
38584983	1465	1473	neuronal	Disease	MESH:D009410
38584983	1564	1581	neuroinflammation	Disease	MESH:D000090862
38584983	1600	1606	Ang-II	Gene	183
38584983	1629	1641	inflammatory	Disease	MESH:D007249
38584983	1659	1670	ceftriaxone	Chemical	MESH:D002443
38584983	1687	1701	excitotoxicity	Disease	
38584983	1710	1732	neuronal deterioration	Disease	MESH:D009410
38584983	1782	1788	EAAT-2	Gene	6506
38584983	1930	1936	Ang-II	Gene	183
38584983	1950	1967	neuroinflammation	Disease	MESH:D000090862
38584983	1969	1980	ceftriaxone	Chemical	MESH:D002443
38584983	1989	1995	EAAT-2	Gene	6506
38584983	2076	2087	ceftriaxone	Chemical	MESH:D002443
38584983	2109	2126	cerebral ischemia	Disease	MESH:D002545
38584983	Positive_Correlation	MESH:D002443	6506
38584983	Association	MESH:D002545	3553
38584983	Association	MESH:D007249	183
38584983	Negative_Correlation	MESH:D002443	MESH:D002545
38584983	Association	MESH:D005947	MESH:D010100
38584983	Negative_Correlation	MESH:D002443	MESH:D009410
38584983	Association	MESH:D018698	6506
38584983	Association	MESH:D002545	7124
38584983	Association	MESH:D009410	6506
38584983	Negative_Correlation	MESH:D010100	MESH:D018698
38584983	Negative_Correlation	MESH:D002443	MESH:D000090862
38584983	Association	MESH:D002545	3569
38584983	Association	MESH:D002545	6506
38584983	Negative_Correlation	MESH:D005947	MESH:D018698
38584983	Association	MESH:D002545	3606
38584983	Association	MESH:D000090862	183

